Abstract
Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Protein & Peptide Letters
Title: Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Volume: 19 Issue: 1
Author(s): Li-Ching Wu, Ping-Heng Hsieh, Jorng-Tzong Horng, Yu-Jen Jou, Chia-Der Lin, Kuang-Fu Cheng, Cheng-Wen Lin and Shih-Yin Chen
Affiliation:
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Abstract: Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Export Options
About this article
Cite this article as:
Wu Li-Ching, Hsieh Ping-Heng, Horng Jorng-Tzong, Jou Yu-Jen, Lin Chia-Der, Cheng Kuang-Fu, Lin Cheng-Wen and Chen Shih-Yin, Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform, Protein & Peptide Letters 2012; 19 (1) . https://dx.doi.org/10.2174/092986612798472929
DOI https://dx.doi.org/10.2174/092986612798472929 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RNA Interference as A Gene-Specific Approach for Molecular Medicine
Current Medicinal Chemistry CXC Chemokines in Angiogenesis Relevant to Chronic Fibroproliferation
Current Drug Targets - Inflammation & Allergy Molecular Dynamics as a Tool in Rational Drug Design: Current Status and Some Major Applications
Current Computer-Aided Drug Design The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Status of Non-Classical Mononuclear Platinum Anticancer Drug Development
Mini-Reviews in Medicinal Chemistry Targeting Mutant KRAS for Anticancer Therapy
Current Topics in Medicinal Chemistry Evaluation of Polygonum bistorta for Anticancer Potential Using Selected Cancer Cell Lines
Medicinal Chemistry Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Current Cancer Drug Targets Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets Biomarker Discovery and Translation in Metabolomics
Current Metabolomics Main Nutritional and Environmental Risk Factors in Children with Leukemia from a Public Hospital of the State of Guanajuato, Mexico
Current Cancer Therapy Reviews Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry